demonstrated, using a MUC1 transgenic mouse model, the potential of specific immune responses to MUC1 for bladder cancer treatment; they found that vaccination with MUC1-specific peptides stimulated a Th1-type cytokine environment and elicited specific T-cell responses to MUC1 (170). This evidence concerns the gene MUC1 and urinary bladder cancer.